FDA puts Neose anemia trial on hold

The FDA has put Neose Technologies' planned clinical trial of its experimental anemia drug on hold as it seeks more information.The Horsham, Pennsylvania-based biotech filed an IND application for NE-180 in June. Neose had hoped to begin a Phase I trial in the third quarter, but said an FDA delay would likely shove that start date back by a quarter.

- read this story from the Philadelphia Business Journal for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.